Clinical trials: Glioblastoma Multiform
Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma)
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of avutometinib and defactinib and to determine the preliminary antitumour activity of avutometinib and defactinib administered at the recommended…
- Conditions
- Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Malignant Primary Gliomas
- Trial name
- 5G-RUBY (NCT06630260)
- Testing
- Avutometinib, Defactinib, Temozolomide
- Where
- 3 sites in United Kingdom
- Volunteers
- 182 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma)
5G-EMERALD: Amivantamab in Malignant Brain Tumours
The purpose of this clinical trial is to evaluate the safety and tolerability of amivantamab and to determine the preliminary antitumour activity of amivantamab administered at the recommended Phase 2 dose (RP2D).
- Conditions
- Malignant Primary Gliomas, Glioblastoma Multiform (Grade IV Astrocytoma), Diffuse Hemispheric Glioma, H3 G34-Mutant, Glioblastoma Multiforme (GBM)
- Trial name
- 5G-EMERALD (NCT06632236)
- Testing
- Amivantamab
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Glioblastoma Multiform, Recurrent Glioblastoma
Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients
Glioblastoma multiform is one of the most invasive and deadly cancers that progresses rapidly and leads to death. Surgery with radiotherapy /chemotherapy, as a treatment approach is ineffective in some cases and is associated…
- Trial name
- NCT05108012
- Testing
- NK cell therapy
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Royan Institute